SSSW(SH:688399) Ge Long Hui·2026-01-30 10:57Core Viewpoint - The company, Shuoshi Biotechnology (688399.SH), is expected to report a significant increase in losses for the fiscal year 2025, with projected net losses ranging from 29.4 million to 44 million yuan, compared to the previous year [1] Financial Performance - The estimated net profit attributable to the parent company for 2025 is projected to be between -29.4 million and -44 million yuan, representing an increase in losses by 27.4 million to 41.9 million yuan compared to the previous year [1] - The expected net profit attributable to the parent company, excluding non-recurring gains and losses, is forecasted to be between -81.9 million and -122.8 million yuan, indicating an increase in losses by 10.1 million to 50.9 million yuan compared to the previous year [1] Business Operations - The company's main business has shown stable development; however, it has faced challenges due to intensified industry competition and ongoing medical procurement reforms, leading to a decrease in revenue from self-produced diagnostic reagents [1] - The value-added tax rate for self-produced diagnostic reagents has been adjusted to 13%, contributing to the decline in revenue [1] - The company is actively implementing cost reduction and efficiency enhancement measures, aiming to maintain a stable overall gross profit margin compared to the previous year [1] Accounts Receivable Management - The company has intensified efforts to collect accounts receivable, resulting in a gradual decrease in the balance of long-aged accounts receivable [1] - There has been a reduction in the reversal of impairment provisions for receivables compared to the previous year [1]